근육 경련 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약물 유형별, 투여 경로별, 유통 채널별, 지역별, 시장 경쟁별(2020-2030년)

Muscle Spasticity Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,511,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,957,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,575,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

근육 경련 세계 시장 규모는 2024년 41억 1,000만 달러로 평가되었고, 예측 기간 동안 55억 3,000만 달러, 2030년까지 5.03%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

세계 근경련 시장은 광범위한 헬스케어 산업에서 역동적으로 진화하고 있는 분야로, 근경련의 복잡한 병태생리에 대처하는 데 초점을 맞추었습니다. 근경련은 비자발적인 근육 수축과 경직이 특징이며, 다발성 경화증, 뇌성마비, 척수 손상과 같은 신경 질환에 기인하는 경우가 많습니다. 이 시장은 신경질환의 유병률 증가, 의료기술의 발전, 고령화 인구 증가 등을 배경으로 수년 동안 큰 성장과 기술 혁신을 이루었습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	41억 1,000만 달러
시장 규모 : 2030년	55억 3,000만 달러
CAGR : 2025-2030년	5.03%
급성장 부문	온라인 약국
최대 시장	북미

시장 성장 촉진요인

신경질환 발생률 증가

주요 시장 이슈

높은 치료비

주요 시장 동향

의식과 교육 향상

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 근육 경련 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 약제 유형별(Baclofen. Botulinum Toxin. Diazepam, Dantrolene Sodium, 기타)
  • 투여 경로별(경구, 근육내, 기타)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 약제 유형별
  • 투여 경로별
  • 유통 채널별
  • 지역별

제5장 아시아태평양의 근육 경련 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 약제 유형별
  • 투여 경로별
  • 유통 채널별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 근육 경련 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 근육 경련 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미의 근육 경련 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 근육 경련 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 근육 경련 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Novartis AG
• Beximco Pharmaceuticals Ltd.
• Zydus Cadila
• Porex Corporation
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Muscle Spasticity Market was valued at USD 4.11 Billion in 2024 and is expected to reach USD 5.53 Billion in the forecast period with a CAGR of 5.03% through 2030. The global muscle spasticity market is a dynamic and evolving sector within the broader healthcare industry, focused on addressing the complex medical condition of muscle spasticity. Muscle spasticity is characterized by involuntary muscle contractions and stiffness, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, or spinal cord injuries. This market has witnessed significant growth and innovation over the years, driven by the increasing prevalence of neurological disorders, advancements in medical technology, and a growing aging population.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.11 Billion
Market Size 2030	USD 5.53 Billion
CAGR 2025-2030	5.03%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

Key Market Drivers

Rising Incidence of Neurological Disorders

The rising incidence of neurological disorders is a pivotal driver behind the burgeoning growth of the global muscle spasticity market. Neurological conditions such as multiple sclerosis (MS), cerebral palsy, spinal cord injuries, stroke, and Parkinson's disease frequently manifest with muscle spasticity, characterized by involuntary muscle contractions and stiffness that significantly impair patients' quality of life.

Multiple sclerosis, in particular, has seen a notable increase in prevalence. According to the World Health Organization (WHO), over 1.8 million people worldwide are affected by MS, with a higher incidence among young adults and females. This autoimmune disease affects the central nervous system and is a leading contributor to muscle spasticity. As the number of MS cases continues to rise, so does the demand for effective treatments to alleviate the debilitating symptoms associated with the condition. Pharmaceutical companies have responded by developing a range of medications aimed at providing relief and improving the daily lives of patients.

Key Market Challenges

High Treatment Costs

High treatment costs pose a significant hurdle in the global muscle spasticity market, impeding the accessibility of care for individuals grappling with this debilitating condition. Muscle spasticity, characterized by involuntary muscle contractions and stiffness, often results from neurological disorders like multiple sclerosis, cerebral palsy, and spinal cord injuries. While treatment options have advanced, the soaring expenses associated with these therapies present a considerable challenge for both patients and healthcare systems. One of the primary issues driving the high treatment costs is the development and production of specialized medications and medical devices tailored for muscle spasticity management. Pharmaceutical companies invest heavily in research and development to create effective drugs that target the condition's symptoms and underlying causes. These innovative treatments, while offering hope for improved patient outcomes, often come with a substantial price tag, making them financially burdensome for many patients.

Key Market Trends

Increasing Awareness and Education

Increasing awareness and education have become instrumental in propelling the global muscle spasticity market forward. In recent years, concerted efforts by advocacy groups, healthcare organizations, and pharmaceutical companies have led to a significant uptick in public understanding and recognition of this debilitating condition. Muscle spasticity, a common symptom in neurological disorders like multiple sclerosis, spinal cord injuries, and stroke, was often overlooked or misunderstood in the past. However, with increased awareness campaigns and educational initiatives, both patients and healthcare providers are now more informed about its prevalence, symptoms, and available treatment options.

Key Market Players

• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Novartis AG
• Beximco Pharmaceuticals Ltd.
• Zydus Cadila
• Porex Corporation
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Muscle Spasticity Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Muscle Spasticity Market, By Drug Type:

• Baclofen
• Botulinum Toxin
• Diazepam
• Dantrolene Sodium
• Others

Muscle Spasticity Market, By Route of Administration:

• Oral
• Intramuscular
• Others

Muscle Spasticity Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Muscle Spasticity Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Muscle Spasticity Market.

Available Customizations:

Global Muscle Spasticity Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Muscle Spasticity Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Others)
  • 4.2.2. By Route of Administration (Oral, Intramuscular, Others)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Drug Type
  • 4.3.2. By Route of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Muscle Spasticity Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type
  • 5.2.2. By Route of Administration
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Muscle Spasticity Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug Type
      • 5.3.1.2.2. By Route of Administration
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Muscle Spasticity Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug Type
      • 5.3.2.2.2. By Route of Administration
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Muscle Spasticity Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug Type
      • 5.3.3.2.2. By Route of Administration
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Muscle Spasticity Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug Type
      • 5.3.4.2.2. By Route of Administration
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Muscle Spasticity Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug Type
      • 5.3.5.2.2. By Route of Administration
      • 5.3.5.2.3. By Distribution Channel

6. Europe Muscle Spasticity Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Muscle Spasticity Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Muscle Spasticity Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Muscle Spasticity Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Muscle Spasticity Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Type
      • 6.3.4.2.2. By Route of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Muscle Spasticity Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Type
      • 6.3.5.2.2. By Route of Administration
      • 6.3.5.2.3. By Distribution Channel

7. North America Muscle Spasticity Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Muscle Spasticity Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Muscle Spasticity Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Muscle Spasticity Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel

8. South America Muscle Spasticity Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Muscle Spasticity Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Muscle Spasticity Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Muscle Spasticity Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Muscle Spasticity Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Muscle Spasticity Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Muscle Spasticity Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Muscle Spasticity Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Muscle Spasticity Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Ipsen Pharma
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Allergan
• 14.3. Acorda Therapeutics, Inc.
• 14.4. Merz Pharma
• 14.5. Novartis AG
• 14.6. Beximco Pharmaceuticals Ltd.
• 14.7. Zydus Cadila
• 14.8. Porex Corporation
• 14.9. Teva Pharmaceutical Industries Ltd
• 14.10. Sun Pharmaceutical Industries Ltd

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료